Prescribe an SGLT2 inhibitor for heart failure in the absence of diabetes?

被引：2
作者：
Koenigsberger, Debra [1 ]
Marquez, Alexander [1 ]
Hughes, Pamela R. [1 ]
Mullen, Rebecca [2 ]
机构：
[1] Nellis AFB Family Med Residency, Las Vegas, NV USA
[2] Univ Colorado, Dept Family Med, Denver, CO 80202 USA
来源：
JOURNAL OF FAMILY PRACTICE | 2021年 / 70卷 / 06期
关键词：
RISK;
D O I：
10.12788/jfp.0235
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
[No abstract available]
引用
收藏
页码：E7 / E9
页数：3
相关论文
共 50 条
  • [41] Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis
    Chambergo-Michilot, Diego
    Tauma-Arrue, Astrid
    Loli-Guevara, Silvana
    IJC HEART & VASCULATURE, 2021, 32
  • [42] Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: Real-world evidence from a nationwide cohort database
    Lo, Shih-Chang
    Kornelius, Edy
    Liao, Pei-Lun
    Huang, Jing-Yang
    Yang, Yi-Sun
    Huang, Chien-Ning
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 200
  • [43] SGLT2 INHIBITORS AND KIDNEYS: MECHANISMS AND MAIN EFFECTS IN DIABETES MELLITUS PATIENTS
    Salukhov, Vladimir V.
    Khalimov, Yurii Sh
    Shustov, Sergey B.
    Popov, Sergey, I
    DIABETES MELLITUS, 2020, 23 (05): : 475 - 491
  • [44] Empagliflozin and Protecting Microvascular Support of Heart Mechanics SGLT2 Inhibition or More?
    Mantsounga, Chris Sorel
    Morrison, Alan R.
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2019, 4 (05): : 592 - 595
  • [45] Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society
    Nakai, Michikazu
    Iwanaga, Yoshitaka
    Kanaoka, Koshiro
    Sumita, Yoko
    Nishioka, Yuichi
    Myojin, Tomoya
    Kubo, Shinichiro
    Okada, Katsuki
    Soeda, Tsunenari
    Noda, Tatsuya
    Sakata, Yasushi
    Imamura, Tomoaki
    Saito, Yoshihiko
    Yasuda, Satoshi
    Miyamoto, Yoshihiro
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [46] Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease
    Ahluwalia, Tarunveer S.
    Ronkko, Teemu K. E.
    Eickhoff, Mie K.
    Curovic, Viktor Rotbain
    Siwy, Justyna
    Eder, Susanne
    Denicolo, Sara
    Mayer, Gert
    Mischak, Harald
    Rossing, Peter
    Persson, Frederik
    KIDNEY INTERNATIONAL REPORTS, 2024, 9 (02): : 334 - 346
  • [47] The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
    Chu, Chang
    Lu, Yong-Ping
    Yin, Lianghong
    Hocher, Berthold
    KIDNEY & BLOOD PRESSURE RESEARCH, 2019, 44 (02) : 149 - 157
  • [48] SGLT2 Inhibitors and Their Antiarrhythmic Properties
    Kolesnik, Ewald
    Scherr, Daniel
    Rohrer, Ursula
    Benedikt, Martin
    Manninger, Martin
    Sourij, Harald
    von Lewinski, Dirk
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)
  • [49] SGLT2 inhibitors: What is new?
    Dumann, Eva
    Menne, Jan
    NEPHROLOGE, 2021, 16 (04): : 241 - 252
  • [50] Diabetic ketoacidosis with SGLT2 inhibitors
    Musso, Giovanni
    Saba, Francesca
    Cassader, Maurizio
    Gambino, Roberto
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 371
12345